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Abstract
Radiation therapy is an indispensable therapeutic modality for various brain diseases. Though endogenous neural stem cells
(NSCs) would provide regenerative potential, many patients nevertheless suffer from radiation-induced brain damage.
Accordingly, we tested beneficial effects of exogenous NSC supplementation using in vivo mouse models that received
whole brain irradiation. Systemic supplementation of primarily cultured mouse fetal NSCs inhibited radiation-induced brain
atrophy and thereby preserved brain functions such as short-term memory. Transplanted NSCs migrated to the irradiated
brain and differentiated into neurons, astrocytes, or oligodendrocytes. In addition, neurotrophic factors such as NGF were
significantly increased in the brain by NSCs, indicating that both paracrine and replacement effects could be the therapeutic
mechanisms of NSCs. Interestingly, NSCs also differentiated into brain endothelial cells, which was accompanied by the
restoration the cerebral blood flow that was reduced from the irradiation. Inhibition of the VEGF signaling reduced the
migration and trans-differentiation of NSCs. Therefore, trans-differentiation of NSCs into brain endothelial cells by the VEGF
signaling and the consequential restoration of the cerebral blood flow would also be one of the therapeutic mechanisms of
NSCs. In summary, our data demonstrate that exogenous NSC supplementation could prevent radiation-induced functional
loss of the brain. Therefore, successful combination of brain radiation therapy and NSC supplementation would provide a
highly promising therapeutic option for patients with various brain diseases.
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Introduction
For many central nervous system diseases including brain
tumors [1,2] and arteriovenous malformations [3], treatment
options are very limited. Surgical intervention is not viable due to
the limited accessibility of the disease location, as well as the high
risk of disturbing vital normal brain functions. The use of systemic
chemotherapeutics is also ineffective because of the largely
impermeable blood-brain barrier (BBB). For example, recent
advances in chemotherapies have led to a relatively better control
of primary tumors, but they still fail to treat metastasis to the brain
since they do not cross the BBB [1,2,4,5,6]. Since new systemic
treatment options become available that increase the longevity of
patients with advanced disease [1], the current annual incidence
rate of 170,000 new brain metastases in the United States [7] is
likely to increase rapidly. High-dose brain radiation therapy is the
primary choice for treating both primary and metastatic brain
tumors [1,2,4,5]. Taken together, radiation therapy remains as the
only remaining indispensable treatment modality.
Incontrasttochemotherapy,radiationtherapyhastheadvantage
of being local and organ-specific. Recent technical advances such as
three-dimensional conformal radiotherapy (3DCRT), intensity-
modulated radiation therapy (IMRT), and gamma knife radiosur-
gery (GKS) allow even further localized and concentrated
treatment. Despite these advances, however, exposure of normal
brain tissues to detrimental effects of radiation is still unavoidable
[4,5]. Furthermore, certain cases, such as diffuse primary brain
tumors or brain metastases with multiple lesions, require the use of
whole-brain radiation therapy (WBRT) that would inevitably lead
to the exposure of normal tissues to high-dose radiation. Normal
brain tissues are sensitive to radiation [4,8–10], and the consequen-
tial brain damage is a severe drawback for the use of radiation
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high-dose WBRT suffered radiation-induced dementia [11], while
others reported significant visual defects, dysarthria, and gait
disturbances [4,8,10]. Therefore, treatment modalities that can
lessen or even prevent radiation-induced brain damage are
imperative to make radiation therapy more appealing for clinical
use and to improve the quality of life of patients.
It is reported that endogenous neural stem cells (NSCs) provide
regenerative potential to irradiated brain tissues [12–14]. An
attractive hypothesis states that NSCs restore the lost functions of
damaged tissues. However, the scarcity of the endogenous NSCs
and the extensive degree of damage due to radiation make
endogenous restoration impractical. It is therefore necessary to
transplant substantial amount of exogenous NSCs to make the cell-
based therapy a viable treatment option. Since NSCs are one of the
most amenable cell sources for neural transplantation [15,16], are
endowed with extensive functional stability and plasticity [12–14],
and can be expanded long-term in vitro [17], we hypothesized that
exogenous supplementation of NSCs could rescue irradiated brains
from functional loss. First, we focused on the WBRT since radiation
exposure of normal brain tissue is higher than those of focused
radiation therapies. It is also clinically relevant since it is the
common procedure for treating the increasing number of brain
metastasis patients. Here, we demonstrated the beneficial effects of
NSC supplementation and elucidated its potential therapeutic
mechanisms. Then, we employed animal models that had focused
radiation therapy, i.e. GKS, and confirmed the therapeutic
mechanisms of NSC supplementation.
Results
1. Primary culture of mouse fetal NSCs expressing green
fluorescent protein (GFP
+ NSCs)
GFP
+ NSCs were primarily cultured from brains of 13.5 day old
GFP transgenic C57BL/6 mouse embryos [18]. In the NSC
culture condition without serum (NeuroBasal Media supplemented
with N2, B27 and EGF), they grew as neurospheres that expressed
NSC markers such as Nestin, Musashi, Sox2, and CD133 (Fig.
S1A, B). When NSCs were maintained in 10% FBS/DMEM for
two weeks, they showed differentiated neural cell morphologies,
lost the expression of the NSC markers, and expressed specific
markers of differentiated neural cells such as Tuj1 (neuron), GFAP
(astrocyte), or Olig2 (oligodendrocyte) confirming their differential
potential (Fig. S1C, D, E).
2. Protective effects of NSCs against the radiation-
induced brain damage
To make animal models representing the radiation-induced
brain damage, 465 Gy whole brain X-irradiations (total 20 Gy,
Day 0, 4, 7, and 11) were applied to C57BL/6 mice (Fig. 1A) using
a device shielding the rest of the animal body from irradiation.
The chronic inflammatory response of microglia after brain
irradiation [19] was observed in our animal models by
immunohistochemistry against CD68 (Day 60, n=5, Fig. S2),
confirming the effects of irradiation on the brain. CD68-positive
cells were observed throughout the irradiated brains. To replenish
the irradiated brains with NSCs, 1610
6 GFP
+ NSCs in 100 ml
PBS were systemically administrated (tail vein injection) at
24 hours after each irradiation (Cont, no irradiation with PBS
injection, n=7; IR, irradiation with PBS injection, n=7; IR +
NSC, irradiation with NSC supplementation, n=6, Fig. 1A).
Eight weeks after the final NSC supplementation, the Morris
water maze test [20] was performed on the Cont, IR, and IR +
NSC groups to analyze short term memory change (Day 67–71),
and corresponding brain structural alterations were examined
(Day 71, Fig. 1A). The IR group mice had significantly reduced
depths of both the granular layer of the dentate gyrus of the
Figure 1. Effects of exogenous NSC supplementation on the
brain structure and function after whole brain irradiation. (A)
Experimental schedules. (B, C) At eight weeks after the last NSC
supplementation, the depth of the granular layer of the dentate gyrus
of the hippocampus (B) and the cerebral cortex (primary somatosensory
cortex, C) were compared. The depth was measured at three random
positions in a section (3 sections for each animal). Bars (B) or arrows (C)
represent examples of the measurements. Cont = no irradiation with
PBS injection (n=7), IR = irradiation with PBS injection (n=7). IR + NSC
= irradiation with NSC supplementation (n=6). * P,0.05. (D) Short
term memory alteration was tested by measuring the length of time to
locate the designated platform in the water bath everyday for five days
(water maze test). * P,0.05. (E) The platform was removed and the time
that the mice stayed at the platform area in one minute was measured
and compared at Day 5 (probe trial). * P,0.05.
doi:10.1371/journal.pone.0025936.g001
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[65.264.0 mm vs 83.065.5 mm (Fig. 1B) and 815.9683.7 mmv s
949.0638.0 mm (Fig. 1C), respectively; P,0.05]. They also
showed significantly poorer short term spatial memory acclima-
tion, indicated by their inability to shorten their latency locating
the designated platform even at Day 5 [Fig. 1D; 48.569.2 seconds
(sec) in Day 1 and 40.3611.1 sec Day 5; compare with Cont’s
46.566.3 sec in Day 1 and 15.3610.6 sec in Day 5]. In addition,
they responded poorly to the probe trial (Day 5), indicated by the
significantly shorter time of staying at the platform area after
platform removal [Fig. 1E; 16.3614.5 sec in one minute (min) vs
37.866.1 sec in one min; P,0.05]. In contrast, the mice with
exogenous NSC supplementation had comparable depths of
granular layer of the dendate gyrus of the hippocampus (Fig. 1B,
78.166.3 mm; P=0.22) and the cerebral cortex (Fig. 1C,
939.4679.8 mm; P=0.83) with the control, with comparable
latency in finding the platform (Fig. 1D, 41.4611.0 sec in Day 1
and 20.0613.8 sec in Day 5) and time of stay at the platform area
(Fig. 1E, 32.366.5 sec in one min). Taken together, these data
suggest that the exogenous NSC supplementation preserved both
the brain structure and function after the whole brain irradiation.
3. Neuro-protective mechanisms of supplemented NSCs
in the irradiated brains
Supplemented NSCs could make their neuro-protective effects
by either secreting various cytokines (paracrine effects) or replacing
damaged neural cells (replacement effects) [16]. Specific effects of
NSC supplementation could be deviated in the animals with
multiple injections of NSCs (Fig. 1A). Therefore, to find out
therapeutic mechanisms of NSCs, PBS or 1610
6 NSCs were
systemically injected to the mice that had one time 5 Gy whole
brainirradiationat24 hoursbeforetheinjection(IRandIR+ NSC,
n=5 for each group). 1610
6 NSCs were also systemically injected
to the mice that did not have whole brain irradiation (NSC group,
n=5). When several neurotrophic factors such as Ang1, CXCL12,
FGF2, IGF1, and NGF were compared between the IR and IR +
NSC groups by quantitative PCR at 72 hours after the NSC
injection, NGF was significantly increased in the brains of the IR +
NSC group (Fig. 2A, right hemispheres of the mice were utilized,
P,0.05), indicating paracrine effects. To determine the fate of
injected GFP
+ NSCs, the brains of the IR + NSC group were
dissociated into single cells, and the expression of differentiated
neural cell markers (GFAP, Olig2 and Tuj1) of GFP
+ cells were
analyzed by flow cytometry [left hemispheres (rostral half) was
utilized]. Seventeen, 21, and 17% of GFP
+ cells of the IR + NSC
group expressed GFAP, Olig2, and Tuj1, respectively (Fig. 2B),
indicating in vivo multi-potent differentiating potential of NSCs.
GFP
+ cells showed similar GFAP, Olig2, or Tuj1 positivity in the
five IR + NSC mice. Co-localization of GFAP, O4 (for
oligodencrocytes), or Tuj1 with GFP was also confirmed immuno-
histochemically in the brains of the IR + NSC mice [arrow heads in
Fig. 2C; left hemispheres (caudal half) of the IR + NSC mice were
Figure 2. Neuro-protective mechanisms of NSCs against the radiation-induced brain damage. (A) Levels of Ang1, CXCL12, FGF2, IGF1
and NGF were compared between the IR and IR + NSC group by real-time PCR. Reference bar (1.0) = IR group. * P,0.05. (B) To determine the fate of
injected GFP
+ NSCs, brains of the IR + NSC mice were dissociated into single cells at 72 hours after the injection and expression of GFAP, Olig2, and
Tuj1of GFP
+ cells was analyzed by flow cytometry. (C, D) Brain sections were prepared from the IR + NSC or NSC mice, and immunohistochemistry
against GFP (green) and GFAP, O4, CD31, vWF, or CD146 (red) was performed. Blue = nuclei.
doi:10.1371/journal.pone.0025936.g002
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+ cells were observed in the brains of
the NSC group (Fig. 2C). Therefore, neuro-protective effects of
supplemented NSCs in the irradiated brains could be mediated by
both paracrine and replacement effects.
4. Trans-differentiation of NSCs into brain endothelial
cells
While supplemented GFP
+ NSCs were differentiated into
astrocytes, oligodendrocytes, or neurons in the irradiated brains,
GFP
+ vessel-like structures were also observed (arrows, Fig. 2C).
Interestingly, these tube-like structures did not co-express GFAP
(Fig. 2C), indicating that they did not originate from GFP
+
perivascular astrocytes. Immunohistochemistry against specific
endothelial markers such as CD31, von Willebrand factor (vWF),
and CD146 (Fig. 2D) confirmed that anti-GFP immunoreactivities
co-localized with the specific markers of endothelial cells. In
contrast, co-localization of GFP with CD31, vWF, or CD146 was
not identified in the NSC group (Fig. 2D). Therefore, injected
NSCs trans-differentiated into brain endothelial cells in the
irradiated brains. It is possible that endothelial cells and/or
endothelial progenitor cells (EPCs) might have contaminated the
primarily cultured NSCs. However, we found few cells positive for
endothelial (CD31) or endothelial progenitor cell markers (CD34
and Sca-1) among our primarily cultured NSCs (Fig. S3),
excluding such possibility. CD31 expression was observed in
11% of GFP
+ cells in the brains of the IR + NSC mice by flow
cytometry (data not shown).
Next, we examined the effects of the whole brain irradiation
and the supplementation of NSCs on the cerebral blood flow to
observe the functional consequences of the trans-differentiation of
NSCs. Positron emission tomography (PET) provides an excellent
in vivo imaging technique for cerebral blood flow measurements
[21,22]. In the PET imaging,
15O labeled water (H2
15O) was
utilized as a tracer. The injected tracer distributions in the brain
and the heart were measured in vivo as a function of time, and the
cerebral blood flow was calculated with an arterial input function
[23]. The H2
15O PET imaging showed that the cerebral blood
flow was reduced significantly at 96 hours after 5 Gy whole brain
irradiation (Fig. 3, Cont=1.1160.17 ml/100 g min, n=3;
IR=0.6760.17 ml/100 g min, n=5, P,0.05), and the reduc-
tion was reversed when 1610
6 NSCs were systemically
supplemented at 24 hours after the irradiation (Fig. 4,
0.9960.22 ml/100 g min, n=3). These data demonstrated that
endothelial cells differentiated from NSCs could take part in the
restoration of the cerebral blood flow reduced by the whole brain
irradiation.
5. Trans-differentiation and migration of NSCs in the
animal models with focal brain irradiation
Although WBRT is widely used to treat brain metastases, the
use of focal brain radiotherapy such as 3DCRT, IMRT, or
radiosurgery, is more popular and increasing. To confirm the
trans-differentiation of NSCs in the brains of animals with focal
brain radiotherapy, we applied focal irradiation to the right
cerebral cortex of C57BL/6 mouse using a GKS apparatus which
can concentrate 50% of the maximal irradiation dose (50%
isodose) within 1 mm (Fig. 4A, Fig. S5). The migration of NSCs to
irradiated brain regions could be additionally analyzed in the
animal models with GKS, since NSCs could be transplanted into
the brain tissues of the opposite hemisphere that had low exposure
to the radiation. Therefore, 1610
5 GFP
+ NSCs in 10 ml HBSS
were stereotactically injected into the opposite brain hemisphere at
24 hours after the focused irradiation (Fig. 4A). When GKS was
not applied, injected NSCs remained in the injected site up to
72 hours (NSC group, Fig. 4C, n=5 for each time point). In the
IR + NSC group (n=5 for each time point), NSCs left the
injection site (arrowheads, Fig. 4C), migrated along the subven-
tricular zone (arrows, Fig. 4C), crossed the midline in the
subventricular zone beneath the corpus callosum at 12 hours
after the injection (arrows in Fig. 4C), and formed GFP
+
microvessels in the irradiated hemisphere (immunohistochemistry
against GFP, Fig. 4B).
Figure 3. Restoration of the cerebral blood flow by supplementation of NSCs. 5 Gy whole brain irradiation was applied to mice, and NSCs
were systemically supplemented at 24 hours after the irradiation. (A) H2
15O was injected into the tail veins of the mice at 72 hours after the injection,
and the injected tracer distributions in the brain and the heart were measured by H2
15O PET imaging. (B) The cerebral blood flow (ml/100 g min) was
determined by analyzing heart and brain signal. Cont, n=3; IR, n=5; IR + NSC, n=3. Height = average. Error bar = standard deviation. * P,0.05.
doi:10.1371/journal.pone.0025936.g003
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and trans-differentiation of NSCs
VEGF is a critical force that drives adult vasculogenesis and one
of the most potent molecules triggering an EPC release from the
bone marrow [24]. We checked the expression of VEGF receptors
on NSCs using semi-quantitative RT-PCR, immunocytochemistry,
and flow cytometry. The expression of the VEGF receptor 2 (Flk-1)
was prominent in NSCs (Fig. S4A–C). VEGF expression and
secretion of NSCs were significantly increased by in vitro irradiation
(Fig. S4D, E). In addition, levels of VEGF were significantly
increased in the irradiated brains (5 and 10 Gy, n=5 for each
group) compared to the control brains (n=5, Fig. S4F). Therefore,
VEGF signaling could be hypothesized to have an important role in
the endothelial cell repopulation process of NSCs.
At 24 hours after the focused irradiation (Fig. 4A), followed by a
systemic administration of ZD6474, a specific Flk-1 inhibitor (Fig.
S6, ZD6476 group, n=5 for each time point) [25], 1610
5 GFP
+
NSCs in 10 ml HBSS were stereotactically injected into the
opposite brain hemisphere. Compared with the IR + NSC group,
inhibition of the VEGF signaling made the injected NSCs to
Figure 4. Trans-differentiation and migration of NSCs in the animal models with focal brain irradiation and effects of the VEGF
signaling on the migration of NSCs. (A) GFP
+ NSCs were injected into the right brain hemisphere stereotactically at 24 hours after focused brain
irradiation to the left hemisphere using a GKS apparatus (50% isodose=3 Gy). The dosimetry for GKS was calculated and presented. The irradiation
focus could be within 0.5 mm of the planned target. (B) Immunohistochemistry against GFP was performed. Injected GFP
+ NSCs migrated into the
contralateral irradiated brain hemisphere and made GFP
+ vessels. (C) The migration route and velocity were analyzed by immunohistochemistry
against GFP (green) at various time points after the injection. NSC = NSC supplementation without GKS (n=5 for each time point), IR + NSC = NSC
supplementation at 24 hours after GKS (n=5 for each time point). Arrowheads = injection tract. Arrows = GFP
+ NSCs migrating in the subventricular
zone. (D) Systemic treatment with a specific Flk-1 inhibitor (ZD6474, 50 mg/kg, oral administration 12 hours after the irradiation) inhibited the
migration of injected GFP
+ NSCs in the focally irradiated brain (n=5 for each time point). Arrows = GFP
+ NSCs migrating in the subventricular zone.
doi:10.1371/journal.pone.0025936.g004
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(Fig. 4D). Even at 24 hours after the injection, NSCs could not
cross the midline (arrows, Fig. 4D).
The effects of Flk-1 inhibition on the trans-differentiation of
NSCs were also analyzed by co-culturing GFP
+ NSCs with human
umbilical venous endothelial cells (HUVECs) on the matrigel [26].
HUVECs made numerous tubes in the differentiation condition,
while NSCs remained as spheres (Fig. S7). When they were co-
cultured, GFP
+ tubes were made effectively (Fig. 5A). However,
treatment of ZD6474 specifically and dose-dependently inhibited
the formation of GFP
+ tube and made GFP
+ NSCs to remain as
spheres (Fig. 5B, P,0.05). Morphologically, the viability of NSCs
on the matrigel was not affected by the treatment of ZD6474, thus
excluding the possibility that the reduction of GFP
+ tube
formation originates from toxic effects. These data suggest that
signaling through the Flk-1 is important in both the migration and
trans-differentiation of NSCs.
Discussion
In this study, we provide in vivo translation data indicating that
exogenous NSC supplementation can be a novel preventive and/
or therapeutic modality against the radiation-induced brain
damage. Most radiation-induced brain damage originates from
medical treatments, yet the unfortunate reality is that the
frequency of radiation therapy for the brain is expected to further
increase in the future. Therefore successful combination of brain
radiation therapy and NSC supplementation would provide a
highly promising therapeutic option for patients with brain
diseases. In addition, accidental exposure to large doses of
irradiation could result in neurological effects and rapid death
[27]. Exogenous NSC supplementation could also be considered
in these cases with other supportive cares. Previously, neuro-
protective effects of NSCs were reported to be mediated by the
secretion of various neurotrophic factors (paracrine effects) and/or
the replacement of damaged neural cells (replacement effects) [16].
In our animal models with radiation-induced brain damage, NGF
was significantly increased in the brain by the supplementation of
NSCs. In addition, transplanted NSCs differentiated into various
neural cells such as neurons, astrocytes and oligodentrocytes in the
irradiated brains. These results suggest that both the paracrine and
replacement effects were implicated in the preventive and/or
therapeutic outcome of NSCs against radiation-induced brain
damage.
Figure 5. Effects of the VEGF signaling on the trans-differentiation of NSCs. (A) GFP-positive NSCs and GFP-negative human umbilical
venous endothelial cells were co-cultured on the matrigel in the differentiation condition of endothelial cells. Effects of Flk-1 inhibition on the trans-
differentiation of NSCs were analyzed by the treatment of ZD6474. (B) Relative GFP
+ tube length (%) and percent of GFP
+ tube of total tube length
were measured and compared * P,0.05. n=3 for each group.
doi:10.1371/journal.pone.0025936.g005
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differentiated into brain endothelial cells. The reduction of the
cerebral blood flow by irradiation was reversed by NSC
supplementation. Therefore, the trans-differentiation into endo-
thelial cells would be one of the preventive and/or therapeutic
mechanisms of NSCs against radiation-induced brain damage. In
the resting state, the brain receives 15–20% of the body’s blood
flow since it is one of the most metabolically active organs [28].
Moreover, the brain is highly dependent on the sufficient blood
supply for its survival and functions [29]. One microvessel
supports numerous neural cells; therefore, the replacement of
damaged endothelial cells could be much more important than the
regeneration of lost neural cells for the maintenance of brain
structures and functions. Since the report about the trans-
differentiation potential of NSCs into endothelial cells [26], its
physiological and clinical implications have remained to be
elucidated. Recently, it was reported that glioblastoma stem-like
cells, which could originate from NSCs and maintain the key
molecular properties of NSCs, show endothelial differentiation in
vitro and in vivo [30,31]. Here, we also demonstrated that NSCs
indeed replace damaged endothelial cells in pathological condi-
tions to prevent structural and functional alterations of the brain.
More importantly, the replacement activity was functionally
relevant, evidenced by the restoration of the cerebral blood flow.
Active vascularization induces and supports the development of
the brain [32]. Therefore, EPCs and/or differentiated endothelial
cells could be included in the NSCs primarily cultured from brains
of 13.5 day old mouse embryos. To exclude this possibility, we
examined the CD31, CD34 and Sca-1 expression of cultured
NSCs, but there were few CD31, CD34, and Sca-1-positive cells.
In addition, NSCs could not make tubes on matrigels in the tube
formation assay, whereas endothelial cells could. This indicates
that cultured NSCs contain, if any, few EPCs or endothelial cells.
VEGF is a critical force that drives vasculogenesis and one of the
most potent molecules triggering EPC release from the bone
marrow [24]. We demonstrated that the VEGF signaling is also
essential in the migration and trans-differentiation of NSCs, which
suggests that VEGF would be a common mediator that recruits
stem cells for the repair of damaged vessels.
In the brain parenchyma, NSCs are closely related with their
niche, of which the endothelial cell is one of the most essential
components [32–34]. Traditionally the niche has been reported to
regulate the self-renewal and fate of NSCs using various kinds of
signaling pathways [32–34]. However our data provoked the
possibility that NSCs might reciprocally have the potential to
reconstruct their niche by themselves. This would further support
the self-renewal and regeneration potential of NSCs, although the
exact functional implications still need to be elucidated.
In vitro long-term expansion capacity [17] and extensive
functional stability and plasticity [12–14] of NSCs have provoked
the possibility of regenerative medicine for various neurological
diseases, such as stroke, spinal cord injury and neurodegenerative
diseases, which currently have few effective therapeutic modalities
[35]. The survival of injected NSCs could be increased when
endothelial cells derived from NSCs would secrete various survival
factors for NSCs. In addition, therapeutic effect could be
potentiated when damaged endothelial cells and neural cells could
be replaced simultaneously by NSCs, because endothelial cells are
also affected by those diseases [36]. Therefore, novel therapeutic
methods which utilize the trans-differentiation capacity of NSCs
would maximize the therapeutic effects of regenerative technolo-
gies using NSCs.
In summary, our data demonstrate that exogenous NSC
supplementation could recover radiation-induced functional losses
of the brain. Although the brain is sensitive to radiation, radiation
therapy remains as an indispensable therapeutic modality for
various brain diseases. Therefore, successful combination of the
brain radiation therapy and NSC supplementation would provide
a highly promising therapeutic option for patients with brain
diseases.
Materials and Methods
1. Primary culture of mouse fetal GFP
+ NSCs
All animal experiments were approved by the appropriate
Institutional Review Boards of the Samsung Medical Center
(Seoul, Korea, approval ID = C-A7-220-3) and conducted in
accord with the ‘National Institute of Health Guide for the Care
and Use of Laboratory Animals’ (NIH publication No. 80-23,
revised in 1996). Brains obtained from 13.5 day old GFP
transgenic C57BL/6 mouse embryos (C57BL/6-Tg(UBC-
GFP)30Scha/J, The Jackson Laboratory) [18] were mechanically
dissociated into single cells. Dissociated cells were cultured in the
NeuroBasal Media (Invitrogen) supplemented with N2, B27
(Invitrogen) and recombinant EGF (50 ng/ml; R&D Systems).
To differentiate cultured cells, cells were plated onto poly-L-lysine
(PLO)-precoated culture dish (Invitrogen) and were subject to
growth in DMEM with 10% fetal bovine serum (10% FBS/
DMEM; Cambrex).
2. Immunocytochemistry
Immunocytochemistry was performed using a standard method.
Briefly, cells were fixed in ice-cold methanol/acetone (1:1) for
10 minutes. After incubation in 0.2% Triton X-100/PBS cells
were treated with primary antibodies; Sox2 (R&D Systems),
Nestin, Musashi, CD133, Tuj1, GFAP, Olig2 (Millipore), and Flk-
1 (Cell Signaling Technology).
3. Whole brain irradiation and systemic supplementation
of NSCs
Four serial whole brain X-irradiations, each with 5 Gy, were
applied to C57BL/6 mice using a blood irradiator (IBL-437C,
CIS-US, Inc.). Mice bodies were shielded with a custom-made
lead shielding device. At 24 hours after each irradiation, 1610
6
GFP
+ NSCs in 100 ml PBS were administrated into the tail vein.
4. Morris water maze test
Mice were trained on Morris water maze [20], three trials per
day for five days. At the start of each trial, one mouse was gently
placed into the water with its head facing the outside of the tank.
The start location was randomized, while ensuring no location was
used repeatedly in consecutive trials. A total of eight start locations
were used for the test, which were evenly spaced around the maze.
SMART video-tracking system (Panlab s.l.u.) was used to measure
the length of time to locate the designated platform in the water
bath. A trial lasted either 60 sec or until the mouse reached the
platform and remained on the platform for 10 sec. If a mouse did
not reach the platform within 60 sec, it was gently guided there by
hand. Mice were placed back in their cage and allowed to rest for
30 sec between trials. One hour after training on Day 5, the
platform was removed and mice were tested with a probe trial; the
time that the mice stayed at the platform area in one minute was
measured.
5. Specimens and immunohistochemistry
The animals were anesthetized, and perfusion fixation was
performed by transcardially perfusing 4uC cold PBS containing
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PBS. The brains were immediately removed, postfixed in the same
fixative overnight and processed for paraffin and frozen embed-
ding using standard experimental procedure. H&E staining was
performed for paraffin sections, and the thickness of the granular
layer of the dentate gyrus of the hippocampus and the cerebral
cortex (primary somatosensory cortex) was measured using a slide
scanner (ScanScopeH CS, Aperio Technologies, Inc.) and an
image analyze software (ImageScope, Aperio Technologies, Inc.).
The thickness was measured at three random positions in a
section, and three sections were analyzed for each animal. Mean
thickness was calculated for each animal and compared. The
frozen blocks were cut into 40 mm coronal sections. Immunohis-
tochemistry was performed with the free-floating method using the
following antibodies: CD68, von Willebrand factor (Abcam), GFP
(Invitrogen), Tuj1, GFAP, O4, CD146 (Millipore) and CD31 (BD
Pharmingen).
6. Quantitative RT-PCR
Total RNAs were isolated from mouse brains, GFP
+ NSCs, and
HUVECs using Total RNA Purification Kit (Qiagen) according to
the manufacturer’s protocol. Equal amounts of RNA were
subjected to cDNA synthesis by using Superscript
TM III First-
Strand Synthesis System (Invitrogen). One microliter of the first-
strand cDNA reaction mixture and 0.2 mM of each primer set [37]
were used for semi-quantitative RT-PCR (35 cycles for VEGF
receptors, 18 cycles for GAPDH). In real-time quantitative PCR,
relative amount of each mRNA was evaluated by Roche LC480
real-time quantitative PCR detection system (Roche) and
calculated following normalization to the GAPDH mRNA. The
primer sequences were described in Table S1.
7. Flow cytometry
Primary antibodies against Sox2 (R&D Systems), Musashi,
Olig2, Tuj1 (Milipore), and GFAP (Santa Cruz biotechnology)
were conjugated with PerCP-Cy5.5 using a conjugation kit (AbD
Serotec). PerCP-Cy5.5 conjugated anti-Nestin, Flk-1 (BD Phar-
mingen), and Sca-1 (eBioscience) antibody and PE conjugated
anti-CD31 and CD34 antibody (BD Pharmingen) were utilized in
the flow cytometry. Brains were enzymatically dissociated into
single cells, and red blood cells were removed by differential
centrifugation. Dissociated cells were fixed and permeabilized by
the Cytofix/Cytoperm
TM kit (BD Biosciences), labeled with
antibodies, and then analyzed by a FACS Calibur machine (BD
Biosciences).
8. H2
15O positron emission tomography (PET) imaging
The PET experiments were performed according to methods
reported previously [23]. An Inveon
TM preclinical small animal
PET system (Siemens Medical Solutions), which allows simulta-
neous imaging of brains and hearts of two mice in one scanner
field of view, was used. Anesthetized animals were moved to the
scanner bed and placed in supine position. The
15O labeled tracers
(H2
15O) were produced by an on-site PETtrace cyclotron (GE
Healthcare) and delivered to the PET room for each PET scan. A
dynamic PET scan (2465 sec frames) was started with the
simultaneous initiation of H2
15O administration (bolus injection
into tail veins, 1 mCi in 0.2 ml saline). The cerebral blood flow
was calculated with an arterial input function by numerically
solving the equations reported previously [23]. The brain regions
of interest were defined as regions with elevated signals in the
control mice (yellow in Fig. 3A). The signals for the same regions
of the IR and IR + NSC mice were analyzed.
9. Focused brain irradiation and orthotopic NSC injection
Focused brain irradiation was applied to the right cerebral
cortex of C57BL/6 mouse using a gamma knife surgery apparatus
(Leksell Gamma KnifeH 4C, Elekta AB). A stereotactic frame
(Leksell frame) for the mouse was made (Fig. 4A), and the
irradiation accuracy and concentrating capacity were tested using
radiosensitive films (Fig. S5). At 24 hours after the focused
irradiation, 1610
5 GFP
+ NSCs suspended in 10 ml HBSS were
stereotactically injected into the mouse brains (2 mm left and
1 mm anterior to the bregma, 2 mm deep).
10. In vitro trans-differentiation of NSCs
HUVECs (American Type Culture Collection) were cultured in
endothelial cell growth medium (EGM) supplemented with EGM
SingleQuots (EGM complete media, Lonza). BD BioCoat
TM
Angiogenesis System (BD Biosciences) was used for the tube
formation test. 2610
4 HUVECs, 2610
4 GFP
+ NSCs, or 1610
4
HUVECs + 1610
4 GFP
+ NSCs in 500 ml EGM complete media
supplemented with 10% FBS were cultured on matrigel in 96-well
plates for 16 hours according to the manufacturer’s protocol. 100,
250, or 500 nM of ZD6474 (LC Labs) was treated to the co-
culture wells. Picture of each well was taken, and the sums of total
tube length were calculated. In parallel, GFP
+ tubes were
quantified. Relative GFP
+ tube lengths and percent of GFP
+ tube
(length of GFP
+ tube/length of total tube) were calculated and
compared.
11. Statistical analysis
Statistical comparisons between groups were performed using
the Student’s t-test. Values of P,0.05 were considered statistically
significant.
Supporting Information
Figure S1 Fetal mouse NSCs expressing GFP were primarily
cultured from brains of 13.5 day old GFP transgenic C57BL/6
mouse embryos. Expression of NSC markers (Nestin, Musashi,
Sox2, and CD133) and differentiated neural cell markers (Tuj1 for
the neuron; GFAP for the astrocyte; Olig2 for the oligodendrocyte)
was examined by immunocytochemistry (A, C, D, E) or flow
cytometry (B). NSCs forming neurospheres in the NSC culture
condition without serum were utilized (A, B). NSCs maintained in
10% FBS/DMEM on PLO-coated slides for overnight (C), 4 days
(D), and 2 weeks (E) were analyzed.
(DOC)
Figure S2 The chronic inflammatory response of microglia after
the brain irradiation was observed in the irradiated mice by anti-
CD68 immunohistochemistry at seven weeks after the last
irradiation. There were few CD68-positive cells in the brains of
the control mice. CD68-positive cells (arrowheads) were magnified
in the insets.
(DOC)
Figure S3 Expression of endothelial or endothelial progenitor
cell markers (CD31, CD34 and Sca-1) of primarily cultured GFP
+
NSCs was analyzed by flow cytometry and compared with those of
endothelial cells (bEND.3). Few primarily cultured GFP
+ NSCs
expressed the endothelial or endothelial progenitor cell markers.
(DOC)
Figure S4 Expression of VEGF receptors in NSCs was analyzed
by semi-quantitative RT-PCR (A), immunocytochemistry (B), and
flow cytometry (C). The VEGF receptor 2 (Flk-1) was predom-
inantly expressed in NSCs while all VEGF receptors were highly
expressed in endothelial cells. GAPDH = internal control. VEGF
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NSCs (E) were analyzed by ELISA and Real-Time PCR,
respectively, at 24 hours after 0, 2, 4, or 8 Gy in vitro irradiation.
n=3 for each group. * P,0.05. (F) Changes in VEGF
concentration of the brain were examined by ELISA at 24 hours
after 0, 5, or 10 Gy whole brain irradiation (n=5 for each group).
*P ,0.05.
(DOC)
Figure S5 The gamma knife surgery device can concentrate
50% of the maximal irradiation dose (50% isodose) within 1 mm.
The concentration capacity was tested using radiosensitive films.
Blue spots represent the intensity of the irradiation and the
intensity is presented as graphs.
(DOC)
Figure S6 Detailed experimental schedule to test the effects of
KDR inhibition on the migration of NSCs is illustrated.
(DOC)
Figure S7 GFP-negative human umbilical venous endothelial
cells (HUVECs) made numerous tubes in matrigels when given
differentiation conditions, while GFP-positive NSCs remained as
spheres.
(DOC)
Table S1 Oligonucleotide primers and probes used for mRNA
expression analysis by real-time PCR.
(DOC)
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